Clinical Trial Search

Primary: Pre-treatment Tumor Proteomic Profile as a Predictor of Response, Stable Disease, or Progressive Disease

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 58.5; 54.3; 55.8; 8.9 Letters

Primary: CoQ10 Levels — 0.38; 0.87 (mcg/mL)

Primary: Pain-Relief at 2 Hours Post-treatment — 56; 65; 66 Participants

Primary: Change of Thrice Weekly Cocaine Free Urine Toxicology From Week 1 to 13 — 6; 0; 3; 2 participants that were cocaine free — p=0.09

Primary: Progression-free Survival — 3.7; 2.8; 4.1 months

Primary: Number of Subjects With Plasma Glucose > 70 mg/dL at 30 Minutes Post-treatment — 7; 6 participants with positive response

Primary: Number of Patients With Mild to Moderate Influenza Disease (MMID) — 6; 29 participants

Primary: Pain-relief Response (Pain Severity of NONE or MILD) at 2 Hours — 20; 29; 34; 33 participants — p=0.0212

Primary: Number of Participants With Local Tolerability Symptoms According to Severity on Baseline — 10; 7; 6; 0 participants

Primary: Peri-Dosing Events — 0; 0; 0; 1 participants

Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) — 18.92 percentage of…

Primary: Child PTSD Symptom Scale (CPSS) — 15.1; 8.9 units on a scale

Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling, Infiltration) Absolute Change in Total Clinical Score (TCS) of Clinical Signs…

Primary: Peak Walking Time (PWT) — 2.2; 1.2 minutes — p=0.238